IgE to common food allergens is associated with cardiovascular mortality in the National Health and Examination Survey and the Multi-Ethnic Study of Atherosclerosis
- PMID: 37943208
- PMCID: PMC10922097
- DOI: 10.1016/j.jaci.2023.09.038
IgE to common food allergens is associated with cardiovascular mortality in the National Health and Examination Survey and the Multi-Ethnic Study of Atherosclerosis
Abstract
Background: In individuals without symptomatic food allergy, food-specific IgE is considered clinically irrelevant. However, recent studies have suggested that galactose-α-1,3-galactose (alpha-gal) IgE is associated with cardiovascular (CV) disease.
Objective: We sought to determine whether sensitization to common food allergens is associated with CV mortality.
Methods: The association between IgE sensitization to foods and CV mortality ascertained to 2019 was examined in the National Health and Examination Survey (NHANES) 2005-2006 and the Wake Forest site of the Multi-Ethnic Study of Atherosclerosis (MESA) cohort; MESA enrolled adults without baseline clinical CV diseases between 2000 and 2002. Total and specific IgE was measured to cow's milk, egg, peanut, shrimp, and a panel of aeroallergens (NHANES), and to cow's milk, alpha-gal, peanut, dust mite, and timothy grass (MESA). Cox proportional hazard models were constructed, adjusting for sex, age, race/ethnicity, smoking, education, and asthma.
Results: A total of 4414 adults from NHANES (229 CV deaths) and 960 from MESA (56 CV deaths) were included. In NHANES, sensitization to at least 1 food was associated with higher CV mortality (hazard ratio [HR], 1.7 [95% confidence interval (CI), 1.2-2.4], P = .005). Milk sensitization was particularly associated (HR, 2.0 [95% CI, 1.1-3.8], P = .026), a finding replicated in MESA (HR, 3.8 [95% CI, 1.6-9.1], P = .003). Restricting analyses in NHANES to consumers of the relevant allergen strengthened food sensitization relationships, unmasking shrimp and peanut sensitization as additional risk factors for CV mortality.
Conclusions: The finding that food sensitization is associated with increased risk of CV mortality challenges the current paradigm that sensitization without overt allergy is benign. Further research is needed to clarify mechanisms of this association.
Keywords: Food sensitization; IgE; cardiovascular disease; mortality.
Copyright © 2023 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Conflict of interest: Dr. Keet receives royalties from UpToDate, funding from the NIH, is an Associate Editor at the Journal of Allergy and Clinical Immunology and serves on the American Board of Allergy and Immunology. Dr. Wilson and Platts-Mills have received assay support from Thermo-Fisher/Phadia, including for this study. Dr. McGowan receives funding from the NIH and has received research support from Regeneron (all funds to the University of Virginia).
Figures
References
-
- Fleischer DM, Bock SA, Spears GC, Wilson CG, Miyazawa NK, Gleason MC, et al. Oral food challenges in children with a diagnosis of food allergy. J Pediatr 2011;158(4):578–83 e1. - PubMed
-
- Vernon ST, Kott KA, Hansen T, Finemore M, Baumgart KW, Bhindi R, et al. Immunoglobulin E Sensitization to Mammalian Oligosaccharide Galactose-alpha-1,3 (alpha-Gal) Is Associated With Noncalcified Plaque, Obstructive Coronary Artery Disease, and ST-Segment-Elevated Myocardial Infarction. Arterioscler Thromb Vasc Biol 2022;42(3):352–61. - PubMed
-
- Wilson JM, Nguyen AT, Schuyler AJ, Commins SP, Taylor AM, Platts-Mills TAE, et al. IgE to the Mammalian Oligosaccharide Galactose-alpha-1,3-Galactose Is Associated With Increased Atheroma Volume and Plaques With Unstable Characteristics-Brief Report. Arterioscler Thromb Vasc Biol 2018;38(7):1665–9. - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- N01 HC095168/HL/NHLBI NIH HHS/United States
- 75N92020D00001/HL/NHLBI NIH HHS/United States
- R01 ES026170/ES/NIEHS NIH HHS/United States
- HHSN268201500003I/HL/NHLBI NIH HHS/United States
- UL1 TR000040/TR/NCATS NIH HHS/United States
- N01 HC095166/HL/NHLBI NIH HHS/United States
- 75N92020D00002/HL/NHLBI NIH HHS/United States
- HHSN268201500003C/HL/NHLBI NIH HHS/United States
- P30 ES010126/ES/NIEHS NIH HHS/United States
- R21 AI151497/AI/NIAID NIH HHS/United States
- N01 HC095161/HL/NHLBI NIH HHS/United States
- 75N92020D00005/HL/NHLBI NIH HHS/United States
- UL1 TR001079/TR/NCATS NIH HHS/United States
- N01 HC095169/HL/NHLBI NIH HHS/United States
- U01 AI125290/AI/NIAID NIH HHS/United States
- N01 HC095167/HL/NHLBI NIH HHS/United States
- N01 HC095159/HL/NHLBI NIH HHS/United States
- 75N92020D00003/HL/NHLBI NIH HHS/United States
- UL1 TR001420/TR/NCATS NIH HHS/United States
- 75N92020D00004/HL/NHLBI NIH HHS/United States
- N01 HC095163/HL/NHLBI NIH HHS/United States
- 75N92020D00007/HL/NHLBI NIH HHS/United States
- N01 HC095162/HL/NHLBI NIH HHS/United States
- 75N92020D00006/HL/NHLBI NIH HHS/United States
- N01 HC095165/HL/NHLBI NIH HHS/United States
- N01 HC095164/HL/NHLBI NIH HHS/United States
- R37 AI020565/AI/NIAID NIH HHS/United States
- N01 HC095160/HL/NHLBI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical